Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting and submission of Unaudited Financial Results (Standalone and Consolidated)
Audit Opinion:
Clean opinion - Unmodified conclusion in respect of limited review for both standalone and consolidated financial results
Auditor’s Comment:
No qualifications or modifications. Auditors noted that consolidated unaudited financial results include interim financial information of 2 subsidiaries which have not been reviewed by their auditors, but these are not material to the Group.
Key Financial Highlights [Rs. Crores]:
Consolidated Results:
Revenue from Operations: ₹381.60 (Q1 FY27) vs ₹387.29 (Q4 FY26) vs ₹319.15 (Q1 FY26)
Total Income: ₹384.29 (Q1 FY27) vs ₹391.98 (Q4 FY26) vs ₹320.13 (Q1 FY26)
Net Profit: ₹16.31 (Q1 FY27) vs ₹9.60 (Q4 FY26) vs ₹10.52 (Q1 FY26)
EPS (Basic): ₹3.52 (Q1 FY27) vs ₹2.20 (Q4 FY26) vs ₹2.46 (Q1 FY26)
EPS (Diluted): ₹3.52 (Q1 FY27) vs ₹2.20 (Q4 FY26) vs ₹2.46 (Q1 FY26)
Other Equity: ₹1,208.37 (as of June 30, 2026)
Standalone Results:
Revenue from Operations: ₹381.60 (Q1 FY27) vs ₹387.29 (Q4 FY26) vs ₹319.15 (Q1 FY26)
Total Income: ₹383.52 (Q1 FY27) vs ₹391.71 (Q4 FY26) vs ₹320.13 (Q1 FY26)
Net Profit: ₹16.99 (Q1 FY27) vs ₹9.73 (Q4 FY26) vs ₹10.53 (Q1 FY26)
EPS (Basic): ₹3.67 (Q1 FY27) vs ₹2.23 (Q4 FY26) vs ₹2.46 (Q1 FY26)
EPS (Diluted): ₹3.67 (Q1 FY27) vs ₹2.23 (Q4 FY26) vs ₹2.46 (Q1 FY26)
Other Equity: ₹1,210.93 (as of March 31, 2026)
Segment-wise Performance:
The Group's operations relate to only one reportable segment: Active Pharmaceutical Ingredient (API). No separate segment disclosure required.
Corporate Actions:
No dividend declarations, share splits, bonus issues, or buybacks announced in this meeting.
Other Significant Information:
Rights Issue Status:
- Total rights issue size: ₹449.95 crores
- Amount raised as of June 30, 2026: ₹442.73 crores
- Breakdown: ₹157.48 crores application money, ₹155.31 crores against first call (May 6, 2025), ₹129.94 crores against final call (May 7, 2026)
- Unpaid amounts: ₹2.18 crores (first call), ₹5.04 crores (final call)
- Proceeds utilized according to Letter of Offer, unutilized balance held in bank accounts
Demerger Plans:
- Board granted in-principle approval on January 24, 2025 to explore demerger of CRAMS and Polymers business
- Incorporated wholly owned subsidiary Synthix Global Pharma Solutions Limited on April 29, 2025 for this purpose
Subsidiaries Included in Consolidation:
1. Shasun USA Inc. (wholly owned subsidiary)
2. Chemsynth Laboratories Private Limited (subsidiary)
3. Synthix Global Pharma Solutions Limited (wholly owned subsidiary)
Exceptional Items:
Q4 FY26 included exceptional item of ₹0.86 crore related to Gratuity and Compensated absences impact under new labour codes